
The Food and Drug Administration (FDA) has accepted for review Phathom Pharmaceuticals’ (NASDAQ:PHAT) New Drug Application (NDA) of its lead drug candidate Vonoprazan for the healing of all grades of erosive esophagitis (EE).
The regulatory agency has assigned standard review for the application and set a target action date of January 11, 2023.